ACRUX LIMITED

0.00%

1.5¢

Market Cap $6.138M

Healthcare Drug Manufacturers - Specialty & Generic

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is... Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.More

Neurizon's (ASX:NUZ) NUZ-001 OLE Study Demonstrates Long-Term Safety and Efficacy Signals

Latest Threads

Tag

Subject

ACR

Ann: Acrux receives $0.4m advance on FY26 R&D Tax Incentive

13/11/25

170

13/11/25

Last post Wooshka

170

ACR

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

12/11/25

728

12/11/25

Last post mwilson25

728

ACR

Ann: Updated September Quarter Activities Statement and App4C

07/11/25

396

07/11/25

Last post bedger

396

ACR

Ann: Licensing partnership in Saudi Arabia for Dapsone 5%, Gel

02/11/25

4.0K

02/11/25

Last post nt_1973_au

4.0K

ACR

Ann: Notice of Annual General Meeting/Proxy Form

24/10/25

Last post

ASX News

ACR

Ann: Notification of AGM date and nomination of directors

03/10/25

635

03/10/25

Last post Slogger

635

ACR

Ann: Notification regarding unquoted securities - ACR

22/09/25

151

22/09/25

Last post

ASX News

151

ACR

Ann: Received $3.04m RDTI rebate for FY25

18/09/25

1.1K

18/09/25

Last post Slogger

1.1K

See All Discussions

Timeline

Acrux receives $0.4m advance on FY26 R&D Tax Incentive
13 Nov 08:21	Share

Updated September Quarter Activities Statement and App4C
04 Nov 09:20	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 11:51	Share

Notice of Annual General Meeting/Proxy Form
24 Oct 08:31	Share

Notification of AGM date and nomination of directors
30 Sep 15:30	Share

Notification regarding unquoted securities - ACR
22 Sep 09:58	Share

Received $3.04m RDTI rebate for FY25
04 Sep 08:24	Share

Appendix 4G and Corporate Governance Statement FY25
29 Aug 08:58	Share

Appendix 4E and Full Year Statutory Accounts FY25
29 Aug 08:57	Share

Licensing partnership in Saudi Arabia for Dapsone 5%, Gel
31 Jul 09:01	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Jul 09:03	Share

Receipt of second advance for FY25 R&D Tax Incentive
03 Jul 09:29	Share

Notification of cessation of securities - ACR
03 Jul 09:24	Share

Application for quotation of securities - ACR
03 Jul 09:23	Share

Change in substantial holding
30 Jun 14:58	Share

App 3Z, Kotsanis
02 Jun 09:05	Share

App 3X, Warmbrunn
02 Jun 09:05	Share

Appendix 3Y Brumley
23 May 09:11	Share

Application for quotation of securities - ACR
23 May 09:10	Share

Notification of cessation of securities - ACR
23 May 09:05	Share

Dapsone 7.5%, Gel launched in the United States
09 May 08:33	Share

Acrux CEO and Managing Director appointment
07 May 09:12	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 10:03	Share

Details of Share Registry address
09 Apr 12:18	Share

Appendix 3Y Dobinson
04 Apr 09:11	Share

Application for quotation of securities - ACR
04 Apr 09:08	Share

Acrux receives $1.73m advance on FY25 R&D Tax Incentive
03 Apr 09:32	Share

Attaching Options final application date 31 March 2025
07 Mar 08:18	Share

Notification of cessation of securities - ACR
06 Mar 08:18	Share

Appendix 3Y Dobinson
04 Mar 08:19	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.5¢		Change 0.000(0.00%)		Mkt cap ! $6.138M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	253500	1.5¢

Sellers (Offers)

Price($)	Vol.	No.
1.6¢	521387	5

View Market Depth

No.	Vol.	Price($)
1	253500	0.015
8	4891165	0.014
4	202422	0.013
11	820083	0.012
2	625000	0.011

Price($)	Vol.	No.
0.016	521387	5
0.017	250000	1
0.018	10861	1
0.019	169348	2
0.020	886181	4

Last trade - 16.21pm 14/11/2025 (20 minute delay)

ACR (ASX) Chart

Day chart unavailable

ACRUX LIMITED

Latest Threads

Timeline

Featured News

Latest Articles

Acrux scores fourth FDA approval, Nitroglycerin Ointment moving into commercialisation

Acrux Ltd has achieved the fourth approval from the US FDA, with its Nitroglycerin Ointment 0.4%, ready for commercialisation

US FDA approves review of Acrux (ASX:ACR) nitroglycerin ointment

Acrux (ASX:ACR) has received approval from the US FDA to review a generic version of its nitroglycerin ointment at 0.4 per cent concentration.

Acrux (ASX:ACR) announces buyout of future Lenzetto royalties

Pharmaceutical company Acrux (ACR) has reached an agreement for the EUR 4.10 million (A$6.41 million) buyout of future royalties for the company's Lenzetto product.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News